 |
 Play Video: The Importance of Insider Buying
|
|
|
| Date | Insider | Price | Amount |
|---|
8-15-2012
Insider Buy |
Jack Goldstein
Director |
$14.38
CAGR »
|
$14,381.00
1,000 shares |
6-1-2012
Insider Buy |
Martin A. Mattingly
Director |
$12.46
CAGR »
|
$12,460.00
1,000 shares |
Also See: Institutional Holders of OGXI
Also See: SEC filings
Below we present the annualized performance delivered by OncoGenex Pharmaceuticals stock since 8-15-2012 (the date of the most recent
insider purchase). The performance of the investment from the time OncoGenex Pharmaceuticals insider buying occurred is the ultimate
test of whether insiders were right about OGXI being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
08/16/2012 |
|
| End date: |
08/02/2017 |
|
| Start price/share: |
$14.51 |
|
| End price/share: |
$0.40 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-97.24% |
|
| Average Annual Total Return: |
-51.49% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$275.64 |
|
| Years: |
4.96 |
|
OncoGenex Pharmaceuticals Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent OncoGenex Pharmaceuticals insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding OGXI
|
|
Free OGXI Email Alerts:
